Chicagoest, I agree there is something seriously wrong. I don't think it is the science because of the BTD and other independent analysis as well as the high quality scientific advisory boards that continue to be a part of the RVX program. I think the fact that the market cap sits likely well below the net present value of tax credits to an acquiring pharma is a direct reflection of the market's view of the very low quality of management and governance, neither of which has any real track record of success in biotech. This combined with the perpetual state of financial uncertainty, lack of transparency and no visible forward progress, I believe, have led to some serious investor fatigue.

Rightly or wrongly I also think the connection to mainland China doesn't help given the current political environment.